Impact of Body Mass Index on Survival of Metastatic Renal Cancer by Salgado Plonski, Jose Javier et al.
 Journal of Kidney Cancer and VHL 2021; 8(2): 49–54  49
KIDNEY CANCER: ORIGINAL ARTICLE
Impact of Body Mass Index on Survival of Metastatic Renal Cancer 
Jose Javier Salgado Plonski, Sergio Fernández-Pello, Laura Rúger Jiménez, Iván González 
Rodríguez, Laura Alonso Calvar, Luis Rodríguez Villamil
Department of Urology, Hospital Universitario de Cabueñes, Gijón, Spain
Abstract
Obesity has been established as a risk factor for renal cell carcinoma (RCC). Recently, studies have described obesity as a probable protecting 
factor in the metastatic stage of RCC. In this study, we assessed the relationship between body mass index (BMI) and overall survival in patients 
under systemic therapy. 
The correlation between BMI and overall median survival was studied in 76 patients diagnosed with metastatic RCC under systemic therapy. 
The groups were divided into overweight and obesity (BMI > 25 kg/m2) and underweight or normal (BMI < 25 kg/m2). Statistical analysis was 
performed using the Cox regression model adjusted by gender. 
A total of 76 patients were studied: 16 women (21%) and 60 men (79%). The median BMI was 27.96 kg/m2; 24 patients (31.6%) had low 
BMI and 52 (68.4%) had high BMI. Median overall survival in the group with BMI > 25 kg/m2 was 17 months (95% confidence interval [CI]: 
13–34 months), while in the group with BMI ≤ 25 kg/m2, it was 14 months (95% CI: 8–20 months). When adjusted by gender, the group with 
BMI > 25 kg/m2 presented a hazards ratio of 0.54 (95% CI: 0.30–0.96), P = 0.044 (Log Rank). 
A high BMI significantly acts as a protecting factor. We observed an increased overall survival of overweight and obese patients within the 
context of metastatic RCC under systemic treatment. These data confirm the findings published in other studies that suggest the role of lipid 
metabolism in this type of tumors. 
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Obesity is a major worldwide health condition linked to 
angiogenic-related diseases such as diabetes, cardiovascu-
lar events, and cancer (1). Although there is a clear trend 
between diabetes, heart diseases, and obesity, the relationship 
between obesity and cancer is confusing, being a risk factor 
in some aspects and a protective factor in others (1, 2).
Some angiogenic growth factors and hormones are pro-
duced by fatty tissues (3), including vascular and endothe-
lial growth factor (VEGF), tumoral necrosis factor (TNF), 
and leptin (4). These factors derived from fatty cells have a 
crucial role in tissue and organ regulation due to angiogenic 
checkpoint control; however, the overexpression of these fac-
tors could not be sufficient to boost it because the feedback 
control of many other activators and inhibitors (5).
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Currently, the mechanisms that connect overweight and 
obesity to different cancer subtypes have been inconclusive. 
It is known that overweight and obesity can cause poten-
tial changes in hormonal metabolism (insulin, Insulin-like 
Growth Factor-1 [IGF-1], and sexual steroids), and proteins 
produced by fatty tissues (adipokines) are also involved in 
immune regulation (leptin), inflammatory response (TNFα, 
interleukin-6 [IL-6], and amyloid A), stromal response, and 
angiogenesis (VEGF-1) as well as extracellular matrix com-
ponents (collagen type 6 [Col VI]) (6).
Although it is reported that overweight and obesity are 
risk factors in the development of Renal Cell Carcinoma 
(RCC), different studies have found a “paradoxical” rela-
tionship between high body mass index (BMI) and improved 
overall survival (OS), and between cancer-specific survival 
(CSS) and relapse-free survival (RFS) compared to lower 
BMI patients (7).
Although a clear cause has not been found to explain this 
“paradoxical” relationship, there is a hypothesis that pro-
poses the power of lipid metabolism over tumor cells (2). 
Several studies have stated that there is an inverse correlation 
between BMI and adiponectin serum levels in RCC. In this 
sense adiponectin is a polypeptide elaborated by the fatty 
tissue and the higher levels could be explained by aggressive 
features and less survival in the context of patients (8). All 
these studies have concluded that adiponectin favors prolif-
eration and checkpoint proteins, and inhibits apoptosis and 
angiogenesis (8, 9).
In the largest series which studied the impact of BMI 
on metastatic RCC patients treated with systemic therapy, 
according to the International Metastatic Renal Cell Cancer 
Database Consortium (IMDC) data, the overall survival sig-
nificantly improved in the overweight patients group (BMI ≥ 
25 kg/m2) compared to normal-weight or low-weight group 
(BMI < 25 kg/m2). The study concluded that overweight and 
obesity behave as independent prognostic factors, and this 
prognostic condition was kept across all IMDC prognostic 
subgroups (10–12).
Our objective was to explain the relationship that exists 
between BMI and overall survival in our metastatic RCC 
patients treated with systemic therapy based on tyrosine 
kinase inhibitors (TKI) and rapamycin inhibitors (mTOR). 
The primary endpoint is the measure of overall survival 
based on BMI levels. The secondary endpoint is the descrip-
tive analysis of clinic and pathologic features of these 
patients.
Material and Methods
This is a single center retrospective cohort study with sur-
vival analysis performed in a regional secondary level hospi-
tal, where physicians of the Urology team studied metastatic 
RCC Caucasian patients treated with systemic therapy 
between 2006 and 2017. The median follow-up time was 58 
months (14 months–118 months). Patients received treat-
ment with sunitinib, pazopanib, temsirolimus, everolimus, 
sorafenib, axitinib, nivolumab, or bevacizumab plus Inter-
feron (IFN) alfa. According to the World Health Organiza-
tion BMI classification, a cutoff  value of 25 kg/m2 was used 
to stratify patients between under or normal weight (BMI < 
25 kg/m2) (13) and overweight or obesity (BMI ≥ 25 kg/m2) 
in different grades in order to make subgroups to analyze 
the relationship of BMI with the median overall survival. 
According to the Memorial Sloan-Kettering Cancer Center 
(MSKCC) classification, the studied variables were as fol-
lows: age, gender, previous nephrectomy, histology subgroup, 
and risk stratification (14). Both groups did not show any 
significant differences except the BMI.
The statistical analysis was performed by using the Cox 
regression model, adjusted by gender. The Kaplan–Meier 
model was used to express survival curves with forest plot 
diagram to study obesity as a prognostic factor. Median 
overall survival was considered as the time from diagnosis of 
metastatic RCC until the death of the patient in the context 
of tumor progression. Confidence Interval (CI) at 95% (95% 
CI) and P < 0.05 were considered statistically significant. 
SPSS version 25.0 (IBM Corp., released 2017, version 25.0, 
Armonk, NY) was used for statistical analysis.
The study was deemed exempt from approval of research 
ethics committee (Servicio de Salud del Principado de 
 Asturias decision tool). As only retrospectively collected 
clinical data was used for analysis, informed consent was 
not sought from patients. The research was conducted in a 
responsible and ethical manner according to accepted stan-
dards and the study was performed in line with the principles 
of the Declaration of Helsinki.
Results
In all, 76 metastatic RCC patients treated with systemic 
treatment with target therapies were included. Demographic, 
clinical, and pathologic features are described in Table 1.
According to the Response Evaluation Criteria in Solid 
Tumors (RECIST), the objective response rate was 36% in 
the first line and 14% for the second line of treatment.
The Kaplan–Meier model analysis revealed a median 
overall survival of  17 months in the group with BMI > 
25 kg/m2 (95% CI: 13–34), while in the group with BMI ≤ 
25 kg/m2, it was 14 months (95% CI: 8–20). Adjusting the 
groups by gender, the differences in overall survival between 
them showed statistically significant differences (P = 0.044; 
Table 2).
The risk analysis of the impact of obesity on the overall 
survival of metastatic RCC patients showed a risk ratio of 
0.54 (95% CI: 0.30–0.96), considering overweight and obe-
sity as protective factors in this context (Figure 1).
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Table 1: Features analyzed according to BMI groups.
Clinicopathologic and 
demographic features 
Total (n = 76) No. of Patients (%)
BMI* ≤ 24.9 kg/m2 (normal or 
under weight) (n = 23)
BMI* > 25 kg/m2 over-
weight, obesity (n = 53)
Age
<60 years 18 (23.68) 5 (21.73) 14 (26.41)
>60 years 58 (76.32) 18 (78.26) 39 (73.58)
Gender
Male 60 (78.94) 17 (73.91) 43 (81.13)
Female  16 (21.05) 6 (26.08) 10 (18.86)
Nephrectomy
Yes 59 (77.63) 19 (82.60) 41 (77.35)
No 17 (22.36) 4 (17.39) 12 (22.64)
Pathologic features
Clear cell carcinoma 70 (92.10) 19 (82.60) 51 (96.22)
Papillary 5 (6.57) 3 (13.04) 2 (3.77)
Chromophobe  1 (1.31) 1 (4.34) 0 (0)
MSKCC **classification (15)
Favorable  22 (28.94) 5 (21.73) 17 (32.07)
Intermediate 49 (64.47) 16 (69.56) 33 (62.26)
Poor 5 (6.57) 2 (8.69) 3 (5.66)
IMDC*** classification (13)
Favorable 27 (35.5) 7 (25.92) 20 (74.07)
Intermediate 37 (48.68) 12 (32.43) 25 (67.56)
Poor 12 (15.78) 7 (58.33) 5 (41.66)
*Body Mass Index, **Memorial Sloan Kettering Cancer Center, ***International Metastasic Renal Cell Carcinoma Database Consortium.
Table 2: Median overall survival according to BMI groups.
Features Median overall survival (months) 95% CI (months)
BMI* ≤ 24.9 kg/m2 (normal or under weight) 14 8–20
BMI* > 25 kg/m2 (overweight, obesity) 17 13–34
P-value 0.044
*Body Mass Index
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metastatic RCC are unknown. In the lipogenesis path-
way, fatty acid synthetase (FASN) has been studied as an 
involved key enzyme. FASN has emerged as a metabolic 
oncogene with an important role in the growth and survival 
of tumors (10). A high BMI has been associated with a low 
expression of FASN gene and the expression of FASN (using 
median as a cut-off  point) has been inversely associated with 
overall survival in patients receiving first- and second-line of 
treatment for metastatic RCC after adjusting of prognostic 
characteristics (11, 12). A fundamental role of perinephric 
fat in modulating tumor response acting as a reservoir of 
activated cells that can be mobilised through the administra-
tion of systemic therapies has been described. Microenviron-
ment in tumors with higher angiogenesis scores makes these 
tumors more susceptible to tyrosine kinase inhibitors. This 


















































Figure 1: The Kaplan–Meier analysis. Hazards ratio of 0.54 (CI 95%: 0.30–0.96).
Discussion
Obesity has been described as a clear and significant risk fac-
tor for the incidence of local RCC being present in 30–40% of 
all cases (2), but in the metastatic scenario this factor could 
behave in a different way. There are multiple studies that have 
shown that a high BMI is related to an increase in the sur-
vival of patients with metastatic RCC. They have concluded 
that overweight and obesity behave as independent prog-
nostic factors (2, 10–12). The largest systematic review and 
meta-analysis that has investigated the association between 
BMI and oncologic outcomes supported the evidence that 
an “obesity paradox” is demonstrated in cancer-specific sur-
vival, overall survival, and relapse-free survival (2).
Several hypotheses have been described but the exact 
mechanisms of how obesity acts to protect patients with 
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patients with clear cell RCC compared to patients having 
normal weight (14, 16, 17). 
Another hypothesis is that obese patients may have a 
higher prevalence of comorbidities that could lead to per-
form image studies, which can lead to a higher rate of 
incidental and early detection of small renal tumors. The 
treatment of small renal tumors could achieve better control 
of the disease, including the metastatic stage.
We studied the relationship between BMI and overall 
survival in patients with metastatic RCC having systemic 
therapy with different lines of  treatment. Results of  our 
study demonstrated that there was a statistically signifi-
cant increase in overall survival in overweight and obese 
patients with metastatic RCC compared to those having 
normal or low weight according to BMI groups. These 
data confirm the findings proposed in other studies that 
suggest the role of  lipid metabolism in this type of  tumors 
(11, 12).
In a descriptive analysis of demographic, clinical, and 
pathologic characteristics of patients, our data are related to 
previously published epidemiologic studies (1).
Limitations
We fairly admit some limitations to this study. First lim-
itation is the limited number of patients. The retrospective 
design could include potential and inherent bias because 
of remarked nature of investigation. In addition, lack of 
adjustment within the study groups regarding pathologic and 
demographics could influence the overall conclusions. Over-
lap between confidence intervals could limit statistical signif-
icance in spite of P-value levels.
This study could lead to the future studies to evaluate the 
prognostic impact of BMI in patients with metastatic RCC 
undergoing systemic therapy in a larger cohort. The future 
study with adequate design, including metabolic biomarkers 
such as leptin or adiponectin, must investigate the impact of 
adipokines on BMI to understand the biologic mechanisms 
responsible for the increased survival in these patients. The 
use of imaging tests, such as computed tomography, could 
benefit in the precision of correct analysis of body composi-
tion compared to BMI.
Conclusions
In conclusion, a high BMI behaves as a protective factor 
with increased overall survival in patients with metastatic 
RCC under systemic treatment.
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